AMLX insider transaction filings
Amylyx Pharmaceuticals, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-14. Screen AMLX transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 12 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 12 legs across 6 filings by 5 insiders — 121,302 shares, $3,483,830 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 9.
- Largest priced transaction: sale of 29,545 shares @ $32.16 ($950,040) by Cohen Joshua B, filed 2026-09-14.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Cohen Joshua B — Co-Chief Executive Officer, Director | 2 | — | 2 legs · 30,464 sh · $980,504 | 1 |
| Klee Justin B. — Co-Chief Executive Officer, Director | 2 | — | 2 legs · 30,464 sh · $980,263 | 1 |
| Mazzariello Gina — Chief Legal Officer | 3 | — | 4 legs · 39,536 sh · $848,374 | 1 |
| FRATES JAMES M — Chief Financial Officer | 2 | — | 2 legs · 10,810 sh · $349,821 | 1 |
| Bedrosian Camille L — Chief Medical Officer | 2 | — | 2 legs · 10,028 sh · $324,868 | 1 |
| Firestone Karen — Director | 1 | — | — | 4 |
Recent Form 4 filings — Amylyx Pharmaceuticals, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-14 | 4 | Cohen Joshua B — Co-Chief Executive Officer, Director | Sale (S): 29,545 @ $32.16 · Sale (S): 919 @ $33.15 | EDGAR |
| 2026-09-14 | 4 | Klee Justin B. — Co-Chief Executive Officer, Director | Sale (S): 29,025 @ $32.13 · Sale (S): 1,439 @ $33.16 | EDGAR |
| 2026-09-14 | 4 | Mazzariello Gina — Chief Legal Officer | Sale (S): 9,525 @ $32.46 · Sale (S): 11 @ $33.34 | EDGAR |
| 2026-09-14 | 4 | FRATES JAMES M — Chief Financial Officer | Sale (S): 9,768 @ $32.27 · Sale (S): 1,042 @ $33.23 | EDGAR |
| 2026-09-14 | 4 | Bedrosian Camille L — Chief Medical Officer | Sale (S): 7,947 @ $32.21 · Sale (S): 2,081 @ $33.09 | EDGAR |
| 2026-09-02 | 4 | Firestone Karen — Director | Option exercise (M): 25,000 @ $1.76 · Option exercise (M): 25,000 @ $5.05 · Option exercise (M): 25,000 (derivative) @ $0 · Option exercise (M): 25,000 (derivative) @ $0 | EDGAR |
| 2026-08-20 | 4 | Mazzariello Gina — Chief Legal Officer | Grant/award (A): 21,284 @ $0 | EDGAR |
| 2026-08-20 | 4 | Klee Justin B. — Co-Chief Executive Officer, Director | Grant/award (A): 60,039 @ $0 | EDGAR |
| 2026-08-20 | 4 | FRATES JAMES M — Chief Financial Officer | Grant/award (A): 22,807 @ $0 | EDGAR |
| 2026-08-20 | 4 | Cohen Joshua B — Co-Chief Executive Officer, Director | Grant/award (A): 60,039 @ $0 | EDGAR |
| 2026-08-20 | 4 | Bedrosian Camille L — Chief Medical Officer | Grant/award (A): 22,807 @ $0 | EDGAR |
| 2026-07-13 | 4 | Mazzariello Gina — Chief Legal Officer | Sale (S): 15,000 @ $18.32 · Sale (S): 15,000 @ $17.61 | EDGAR |
| 2026-06-08 | 4 | Zeiher Bernhardt G — Director | Grant/award (A): 24,372 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Firestone Karen — Director | Grant/award (A): 24,372 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | FONTEYNE PAUL R. — Director | Grant/award (A): 24,372 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Quimi Daphne — Director | Grant/award (A): 24,372 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | MILNE GEORGE M JR — Director | Grant/award (A): 24,372 (derivative) @ $0 | EDGAR |
| 2026-05-26 | 4 | Firestone Karen — Director | Purchase (P): 3,800 @ $13.51 | EDGAR |
| 2026-03-09 | 4 | Cohen Joshua B — Co-Chief Executive Officer, Director | Grant/award (A): 248,865 @ $0 · Grant/award (A): 373,295 (derivative) @ $0 | EDGAR |
| 2026-03-09 | 4 | Mazzariello Gina — Chief Legal Officer | Grant/award (A): 74,660 @ $0 · Grant/award (A): 111,990 (derivative) @ $0 | EDGAR |
| 2026-03-09 | 4 | Klee Justin B. — Co-Chief Executive Officer, Director | Grant/award (A): 248,865 @ $0 · Grant/award (A): 373,295 (derivative) @ $0 | EDGAR |
| 2026-03-09 | 4 | Bedrosian Camille L — Chief Medical Officer | Grant/award (A): 95,990 @ $0 · Grant/award (A): 143,985 (derivative) @ $0 | EDGAR |
| 2026-03-09 | 4 | FRATES JAMES M — Chief Financial Officer | Grant/award (A): 95,990 @ $0 · Grant/award (A): 143,985 (derivative) @ $0 | EDGAR |
| 2026-03-04 | 4 | Klee Justin B. — Co-Chief Executive Officer, Director | Sale (S): 29,282 @ $14.47 | EDGAR |
| 2026-03-04 | 4 | Cohen Joshua B — Co-Chief Executive Officer, Director | Sale (S): 29,282 @ $14.48 | EDGAR |
| 2026-03-04 | 4 | Mazzariello Gina — Chief Legal Officer | Sale (S): 6,844 @ $14.52 | EDGAR |
| 2026-03-04 | 4 | Bedrosian Camille L — Chief Medical Officer | Sale (S): 6,461 @ $14.58 | EDGAR |
| 2026-03-04 | 4 | FRATES JAMES M — Chief Financial Officer | Sale (S): 7,909 @ $14.52 | EDGAR |
| 2026-02-25 | 4 | Mazzariello Gina — Chief Legal Officer | Sale (S): 3,419 @ $14.14 | EDGAR |
| 2026-02-04 | 4 | Cohen Joshua B — Co-Chief Executive Officer, Director | Sale (S): 15,500 @ $14.68 | EDGAR |
| 2026-02-04 | 4 | Mazzariello Gina — Chief Legal Officer | Sale (S): 3,448 @ $14.65 | EDGAR |
| 2026-02-04 | 4 | Klee Justin B. — Co-Chief Executive Officer, Director | Sale (S): 15,500 @ $14.69 | EDGAR |
| 2026-02-04 | 4 | FRATES JAMES M — Chief Financial Officer | Sale (S): 3,557 @ $14.65 | EDGAR |
| 2026-01-20 | 4 | Cohen Joshua B — Co-Chief Executive Officer, Director | Option exercise (M): 197,182 @ $7.57 · Sale (S): 136,193 @ $13.59 · Option exercise (M): 2,818 @ $7.57 · Sale (S): 1,974 @ $13.83 · Option exercise (M): 197,182 (derivative) @ $0 · Option exercise (M): 2,818 (derivative) @ $0 | EDGAR |
| 2026-01-20 | 4 | Klee Justin B. — Co-Chief Executive Officer, Director | Option exercise (M): 197,153 @ $7.57 · Sale (S): 136,193 @ $13.58 · Option exercise (M): 2,847 @ $7.57 · Sale (S): 1,995 @ $13.89 · Option exercise (M): 197,153 (derivative) @ $0 · Option exercise (M): 2,847 (derivative) @ $0 | EDGAR |
| 2026-01-14 | 4 | MILNE GEORGE M JR — Director | Gift (G): 17,780 @ $0 | EDGAR |
| 2026-01-08 | 4 | Cohen Joshua B — Co-Chief Executive Officer, Director | Sale (S): 7,715 @ $11.09 | EDGAR |
| 2026-01-08 | 4 | Klee Justin B. — Co-Chief Executive Officer, Director | Sale (S): 7,715 @ $11.09 | EDGAR |
| 2026-01-08 | 4 | FRATES JAMES M — Chief Financial Officer | Sale (S): 3,326 @ $11.11 | EDGAR |
| 2025-12-23 | 4 | Firestone Karen — Director | Purchase (P): 8,100 @ $12.45 | EDGAR |
| 2025-12-03 | 4 | Bedrosian Camille L — Chief Medical Officer | Sale (S): 6,580 @ $14.35 | EDGAR |
| 2025-10-02 | 4 | Klee Justin B. — Co-Chief Executive Officer, Director | Sale (S): 29,775 @ $14.37 · Sale (S): 200 @ $15.01 | EDGAR |
| 2025-10-02 | 4 | Mazzariello Gina — Chief Legal Officer | Sale (S): 8,828 @ $14.58 | EDGAR |
| 2025-10-02 | 4 | Cohen Joshua B — Co-Chief Executive Officer, Director | Sale (S): 29,733 @ $14.34 · Sale (S): 200 @ $15.00 | EDGAR |
| 2025-10-02 | 4 | Bedrosian Camille L — Chief Medical Officer | Sale (S): 12,039 @ $14.58 | EDGAR |
| 2025-10-02 | 4 | FRATES JAMES M — Chief Financial Officer | Sale (S): 10,558 @ $14.65 | EDGAR |
| 2025-08-14 | 4 | Mazzariello Gina — Chief Legal Officer | Sale (S): 15,000 @ $8.07 · Sale (S): 15,000 @ $8.34 | EDGAR |
| 2025-06-09 | 4 | Zeiher Bernhardt G — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Quimi Daphne — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | MILNE GEORGE M JR — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Amylyx Pharmaceuticals, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-08 | 8-K | 1.01 — Entry into a Material Definitive Agreement | EDGAR |
| 2026-08-20 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-18 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-18 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-04 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-24 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-03 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-08 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=AMLX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →